Basel, Switzerland
Basel, Switzerland

Time filter

Source Type

Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2011.2.4.3-3 | Award Amount: 7.70M | Year: 2011

Modern lifestyle has dramatically changed the daily rhythms of life. Physical activity, diet and light exposure are no longer restricted to daytime hours, as technical and economical de-mands fuel the necessity to work outside usual working hours. Recent studies show that al-tered light exposure, shifted exercise patterns and untimely food intake following extended active periods into the night disturb the circadian clocks and severely disrupt endocrine and metabolic processes, contributing to an increased risk of type 2 diabetes/obesity. Especially shift workers constituting 20% of the European working population are affected by this prob-lem. Until now only few studies investigating circadian rhythm disturbances in the context of type 2 diabetes/obesity have been conducted in man. Within EuRhythDia a consortium of leading scientists supported by research-intensive SMEs aims to close this gap. The objective of the project is to achieve breakthroughs in the understanding of the causality between inner clock rhythm disturbances and the development of type 2 diabetes/obesity, and to verify whether re-setting the circadian clock through lifestyle interventions (exercise, diet, light exposure and melatonin intake) alters cardiometabolic risk to a clinically relevant degree. The project is based on shift workers as a model and combines genetic, epigenetic, proteomic, metabolomic, physiological, and clinical approaches. The consortium has direct access to well characterised human data incl. individuals predisposed to type 2 diabetes via LUPS co-hort. Additional small interventional and validation cohorts of shift workers and high risk juveniles will be recruited, and supportive animal studies will be conducted. Through the de-velopment of novel diagnostic assays enabling identification of patients at risk and elaboration of targeted prevention guidelines focusing on shift workers and juveniles, EuRhythDia will contribute to a positive impact on European citizens` health.


Grant
Agency: European Commission | Branch: FP7 | Program: CP | Phase: ENV.2012.6.4-3 | Award Amount: 11.65M | Year: 2012

This project aims to predict individual disease risk related to the environment, by characterizing the external and internal exposome for common exposures (air and drinking water contaminants) during critical periods of life, including in utero. A large amount of health data is now available from longitudinal cohorts in both children and adults, with detailed information on risk factors, confounders and outcomes, but these are not well linked with environmental exposure data. The exposome concept refers to the totality of environmental exposures from conception onwards, and is a novel approach to studying the role of the environment in human disease. This project will move the field forward by utilising data on individual external exposome (including sensors, smartphones, geo-referencing, satellites), and omic profiles in an agnostic search for new and integrated biomarkers. These tools will be applied in both experimental short-term studies and long-term longitudinal studies in humans. The ultimate goal is to use the new tools in risk assessment and in the estimation of the burden of environmental disease. The involvement of two SMEs, one specialized in sensors and smartphone development, the other in complex data integration, will increase the chances of a successful impact on European Public Health. This multidisciplinary proposal combines: development of a general framework for the systematic measurement of the internal and external exposome in Europe in relation to air and water contamination, as a way to reduce uncertainty in risk assessment and to address the effects of mixtures and complex exposures; evaluation of health outcomes and key physiological changes in short-term studies (including a randomized trial) and life-course studies with a large amount of information on diet, physical activity and anthropometry; evaluation of the burden of disease in the European population, based on state-of-the-art assessment of population exposures.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2013.1.3-1 | Award Amount: 15.99M | Year: 2013

HeCaToS aims at developing integrative in silico tools for predicting human liver and heart toxicity. The objective is to develop an integrated modeling framework, by combining advances in computational chemistry and systems toxicology, for modelling toxic perturbations in liver and heart across multiple scales. This framework will include vertical integrations of representations from drug(metabolite)-target interactions, through macromolecules/proteins, to (sub-)cellular functionalities and organ physiologies, and even the human whole-body level. In view of the importance of mitochondrial deregulations and of immunological dysfunctions associated with hepatic and cardiac drug-induced injuries, focus will be on these particular Adverse Outcome Pathways. Models will be populated with data from innovative in vitro 3D liver and heart assays challenged with prototypical hepato- or cardiotoxicants; data will be generated by advanced molecular and functional analytical techniques retrieving information on key (sub-)cellular toxic evens. For validating perturbed AOPs in vitro in appropriate human investigations, case studies on patients with liver injuries or cardiomyopathies due to adverse drug effects, will be developed, and biopsies will be subjected to similar analyses. Existing ChEMBL and diXa data infrastructures will be advanced for data gathering, storing and integrated statistical analysis. Model performance in toxicity prediction will be assessed by comparing in silico predictions with experimental results across a multitude of read-out parameters, which in turn will suggest additional experiments for further validating predictions. HeCaToS, organized as a private-public partnership, will generate major socioeconomic impact because it will develop better chemical safety tests leading to safer drugs, but also industrial chemicals, and cosmetics, thereby improving patient and consumer health, and sustaining EUs industrial competitiveness.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: NMP.2012.1.3-2 | Award Amount: 1.39M | Year: 2013

MOD-ENP-TOX project is a multidisciplinary project aiming to accomplish the following objectives: (i) to develop a novel and rational Modelling Assay Platform (MAP) which can be used as a Risk Indicator tool to predict the toxicity of metal-based NPs (MeNPs), and (ii) to demonstrate the feasibility of a MAP prototype on a shortlist of MeNPs - which can be further developed to screen the toxicity of a large number ENPs. Based on the concept of Integrating Testing Strategies (ITS), the proposed generic MAP combines two main and complimentary paradigms: (1) a novel Computational Modelling Package (CMP) based on structural, mechanistic, as well as kinetic modelling tools and (2) an innovative high content screening (HCS) strategy that allows performing multiplexed streamlined assays for calibration, refinement and validation of the computed models. First a series of classification algorithms will be applied to identify MeNPs with similar toxicity patterns, then computational modelling tools will be developed to establish a more rational relationship between MeNPs descriptors and their toxicity in a dynamic and quantitative way. An in-vitro/in-vivo HCS paradigm will be developed as a scalable assessment tool to calibrate and validate the predictive power of the CMP using subsets of the training set or independent set of MeNPs (validation set) respectively.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.4.2-1 | Award Amount: 7.88M | Year: 2013

Atherosclerosis and its most disabling sequelae, coronary artery disease (CAD) and stroke, are leading causes of death in Europe. Until now, preventive and therapeutic interventions for these diseases aim at ameliorating the effects of established cardiovascular risk factors. More recently, results of genome-wide association (GWA) studies added to our perception of mechanisms leading to atherosclerosis. At present, over 40 CAD and several genomic risk loci have been identified, the majority through efforts led by the applicants. Some genes at these loci work through known risk factors such as lipids and, in fact, are already established or evolving treatment targets. However, this is not true for the majority of risk variants, which implies that key pathways leading to atherosclerosis are yet to be exploited for therapeutic intervention. This EU network (CVgenes@target), which brings together an equal number of SME- and academic partners, will utilize genomic variants affecting atherosclerosis risk for identification of both underlying genes and affected pathways in order to identify, characterize, and validate novel therapeutically relevant targets for prevention and treatment of CAD and stroke. In programme 1 we will investigate molecular mechanisms at the genomic loci in order to further unravel causal genes, in programme 2 we will explore in vitro and in vivo whether the pathways disturbed by causal genes are suitable for therapeutic intervention, and in programme 3 we will establish assays and initiate high throughput screens to tackle therapeutically attractive targets. Our resources including large OMICs and state-of-the-art bioinformatics platforms as well as multiple, already established in vitro and in vivo models support the feasibility of the approach. In fact, two genomic risk loci (ADAMTS7 (CAD); HDAC9 (stroke and CAD)), both identified in GWA studies under direction of the applicants, already revealed attractive targets for therapeutic intervention.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2013.2.1.1-1 | Award Amount: 16.16M | Year: 2013

Recently intense research identified around 4,000 single nucleotide polymorphisms (SNPs) associated with human age related diseases such as metabolic disorders. Despite their highly significant association to pathology, the functional role of these genetic variants is, in most cases, yet to be elucidated. The evolutionary distance of most animal models from humans represents a major limitation for the functional validation of these SNPs. To overcome these difficulties, HUMAN will generate mouse models carrying human hepatocytes or pancreatic cells from either primary cells (hepatocytes) or induced pluripotent stem cells (iPSCs). This innovative approach offers the unique possibility of studying function of genetic risk variants associated with metabolic diseases in an integrated living system (the mouse body), but within human-derived organs, i.e. liver and pancreas. iPSCs used to generate hepatocytes and cells will derive from extreme phenotypes, i.e. patients affected by severe metabolic diseases such as type 2 diabetes (T2D) or subjects selected for exceptional healthy longevity (subjects over 105 years and offspring of nonagenarian sibships) all fully clinically and metabolically characterised and genotyped; they will be selected according to the best combination of risk and protective alleles. We will test the effect of different nutritional regimes (e.g. high fat diet, caloric restriction), to disentangle the complex molecular mechanisms and circuitry across organs (e.g. hypothalamus-liver axis) which lead to pathology. HUMAN associates a core of outstanding basic research institutions to leading European biotech SMEs, and has the capability to produce at least 500 humanised mice. HUMAN will generate iPSCs biobanks and comprehensively manage all associated information. HUMAN is uniquely situated to drive innovation towards a better knowledge of the genetic basis of human metabolic diseases, thereby contributing to healthier aging of European citizens.


News Article | February 17, 2017
Site: www.prnewswire.co.uk

Research and Markets has announced the addition of the "Cell Analysis Global Market - Forecast to 2023" report to their offering. The cell analysis market is expected to grow at high single digit CAGR to reach $47,088 million by 2023. The major factor influencing the growth is enhanced precision of cell imaging and analysis systems which in turn reduce time and cost of drug discovery process. In addition, the factors like increasing incidence of cancer, increasing government investments, funds, and grants, availability of reagents and cell analysis instruments are driving the growth of the market. However, the major market restraints include high capital investments and a shortage of skilled labor for the high content screening procedure. The biggest opportunities for this market is the emerging APAC market, high content screening services provided by contract research organizations, automation in cancer research for its early diagnosis and reduction of cost in the cancer treatment. The cell analysis global market is a competitive and all the active players in this market are involved in innovating new and advanced products to maintain their market shares. The key players in the cell analysis global market include Agilent Technologies, Inc. (U.S.), Becton Dickinson and Company (U.S.), Bio-Rad Laboratories (U.S.), Danaher Corporation (U.S.), GE Healthcare (U.K.), Merck KGAA (Germany), Olympus Corporation (Japan), PerkinElmer, Inc. (U.S.), Promega Corporation (U.S.), Qiagen N.V. (Netherlands) and ThermoFisher Scientific, Inc. (U.S.). In order to offer the products with better software, most of the players in the cell analysis market are collaborating with companies and educational institutions. - 4titude (U.K.) - AB Sciex (U.S.) - Abbott Laboratories, Inc. (U.S.) - Abcam PLC (U.S.) - Abdos (India) - Abnova Corporation (Taiwan) - ACEA Bioscience, Inc (U.S.) - Active Motif (U.S.) - Adnagen (U.S.) - Advanced Cell Diagnostics (U.S.) - Agilent Technologies, Inc. (U.S.) - Alere (U.S.) - Analytik Jena AG (Germany) - Apocell (U.S.) - Applied Microarrays (U.S.) - Ausragen (U.S.) - Auxilab S.L (Spain) - Avantes BV (Netherlands) - Aven Inc (U.S.) - Aviva Bioscience (U.S.) - Becton Dickinson and Company (U.S.) - BGI (China) - Bibby Scientific Limited (U.K.) - Bio Care Medical LLC (U.S.) - BioDot Inc. (U.S.) - Biofluidica (U.S.) - Biologics (China) - BioMerieux SA (Germany) - Bio-Rad Laboratories (U.S.) - Bioron (France) - Biosearch Technologies (U.S.) - BioView (Israel) - BMS microscopes (Netherlands) - Bruker (U.S.) - Canopus Bioscience (U.S.) - Capp ApS (Denmark) - Carl Zeiss AG (Germany) - Cell Signaling Technology, Inc. (U.S.) - Cell-Vu (U.S.) - Cherry Biotech (France) - Cisbio Bioassays (France) - Clearbridge BioMedics (Singapore) - Corning Inc (U.S.) - Creatv Microtech inc (U.S.) - Cyflogic (Finland) - Cynvenio Biosystems (U.S.) - Cytognos S.L. (Spain) - DaAn Gene (China) - Danaher Corporation (U.S.) - Danish Micro Engineering (Denmark) - Diagenode (Netherlands) - DiscoveRx (U.S.) - Domel (Slovenia) - Dragon Laboratory Instruments Ltd (China) - eBioscience, Inc., (U.S.) - Eppendorf (Germany) - Etaluma, Inc (U.S.) - Eurofins Scientific (Luxembourg) - EXIQON (Denmark) - FEI Company (U.S.) - Fluidgm Corporation (U.S.) - Fluxion Biosciences (U.S.) - GE Healthcare (U.K.) - Genedata AG (Switzerland) - Genemed Biotechnologies Inc (U.S.) - General Biologicals (Taiwan) - Gyros AB (Sweden) - Handyem (Canada) - Hausser Scientific (U.S.) - Herolab GmbH (Germany) - Hettich lab technology (Germany) - Hoffmann-La Roche (Switzerland) - HORIBA, Ltd. (Japan) - Illumina (U.S.) - Immunodiagnostics systems (France) - Jasco (U.S.) - Jena Biosciences (Germany) - JEOL, Ltd. (Japan) - Jasco Analytical Instruments (U.S.) - Kapa Biosystems (U.S.) - Keyence Corporation (U.S.) - Kyratec (Australia) - Labcon (U.S.) - Labnet International, Inc (U.S.) - Lubio Science (Switzerland) - Luminex Corporation (U.S.) - LW Scientific (U.S.) - Macrogen Inc (South Korea) - Medical Econet (Austria) - Meijo techno (U.K.) - Merck KGaA (Germany) - Mettler-Toledo, Inc. (U.S.) - Micro-shot Technology Ltd (China) - Miltenyil Biotec (Germany) - Nanostring Technologies (U.S.) - New England Biolabs (U.S.) - Nikon Corporation (Japan) - Olympus Corporation (Japan) - Optika SRL., (Italy) - Ortho Clinical Diagnostics (U.S.) - Ortoalresa (Spain) - Oxford Nanopore Technologies, Ltd. (U.K.) - Pacific Biosciences (U.S.) - Panagene (South Korea) - Park Systems (Korea) - PerkinElmer Inc (U.S.) - Pheonix (U.S.) - PicoQuant GmbH (Germany) - Promega Corporation (U.S.) - Qiagen N.V. (Netherlands) - Quest Diagnostics (U.S.) - R&D Systems (U.S.) - Rain Dance Technologies (U.S.) - Rheonix (U.S.) - Rigaku Corporation (Japan) - RR Mechatronics (Netherlands) - Sacace Biotechnologies (Italy) - Sanyo (Japan) - Scienion (Germany) - Scientific Specialities Inc (U.S.) - Seegene (South Korea) - Seimens Healthcare (Germany) - Separation Technology, Inc (U.S.) - Shimadzu Scientific Instruments (Japan) - Sigma Laborzentrifugen GmbH (Germany) - Sohn GmbH (Germany) - Sony Biotechnology (U.S.) - Sprenson Bioscience (U.S.) - Stemcell Technologies (Canada) - Sysmex (Japan) - Tecan (Switzerland) - The Western Electric & Scientific Works (India) - ThermoFisher Scientific Inc (U.S.) - Thorlabs (U.S.) - Toyo Gosei Co., Ltd (Japan) - TrimGen Genetic Diagnostics (U.S.) - Vision Scientific Co Ltd (Korea) - Visitron Systems Gmbh (Germany) - Waters Corporation (U.S.) - Yokogawa Electric Corporation (Japan) - Zymo Research (U.S.) For more information about this report visit http://www.researchandmarkets.com/research/ngm5k6/cell_analysis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.3.1-2 | Award Amount: 7.63M | Year: 2014

Invasive fungal disease (IFD) is a leading cause of morbidity and mortality in the growing number of immunocompromised individuals, including particularly cancer patients, and bone-marrow or organ transplant recipients. The majority of IFD events are still caused by Candida and Aspergillus species, but there is an increasing incidence of resistant or previously uncommon moulds, yeasts and Zygomycetes. Timely pathogen detection is a prerequisite for effective therapy in patients with IFD. FUNGITECT will focus on this medical priority and develop, validate and market a specific set of novel molecular diagnostic tests for IFD targeting fungal DNA-, RNA- and protein motifs, as well as the enzymatic activity of fungal pathogens. Additionally, FUNGITECT will provide a unique opportunity to establish and implement highly effective diagnostic assays supported by Next-Generation Sequencing and a bioinformatics service platform, facilitating optimized treatment strategies adapted to individual patient requirements with the following paramount aims: i) to provide the diagnostic basis for stratified and timely administration of the most appropriate antifungal therapy permitting improved management of patients with IFD, ii) to decrease the rate of overtreatment and the ensuing adverse side effects including fungal resistance, and iii) to help reduce the enormous healthcare costs for clinical antifungal therapy. The consortium includes leading academic research institutions, SMEs and Industry already successfully positioned in the market.


Grant
Agency: European Commission | Branch: FP7 | Program: CPCSA | Phase: INFRA-2011-1.2.2. | Award Amount: 3.68M | Year: 2011

The EU nowadays witnesses increasing demands with regard to chemical safety. In particular, animal-based test models need to be replaced preferably by robust, non-animal assays in vitro/in silico which better predict human toxicity in vivo, are less costly, and are socially better acceptable. Consumers and patients health will benefit and competitiveness of EUs chemical manufacturing industry will be increased. For developing such assays, FP6/FP7 Research Programmes are exploiting the revenues of data-dense genomics technologies. However, till date, there is no infrastructure foreseen which aims at capturing all data produced by toxicogenomics (TGX) projects, in a standardized, harmonized and sustainable manner. Data may thus evaporate. The lack of such an infrastructure also prevents innovative breakthroughs from meta-analyses of joint databases and systems modeling.\nDriven by these needs of the TGX research community, diXa will focus on networking activities, for building a web-based, openly accessible and sustainable e-infrastructure for capturing TGX data, and for linking this to available data bases holding chemico/physico/toxicological information, and to data bases on molecular medicine, thus crossing traditional borders between scientific disciplines and reaching out to other research communities. To advance data sharing, diXa will ensure clear communication channels with and deliver commonly agreed core service support to the TGX research community, by providing SOPs for seamless data sharing, and by offering quality assessments and newly developed tools and techniques for data management, all supported by hands-on training. Through its joint research initiative, by using data available from its data infrastructure, diXa will demonstrate the feasibility of its approach by performing cross-platform integrative statistical analyses, and cross-study meta-analyses, to create a systems model for predicting chemical-induced liver injury.


Grant
Agency: European Commission | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2012.1.2-1 | Award Amount: 7.65M | Year: 2012

CLINICAL NEED Every year in the EU ~45,300 and 330,000 women are diagnosed with ovarian and breast cancer respectively & 28,800 and 90,000 of these two groups of women will die as a consequence of these diseases. Currently there are no tools available that allow for: a) Effective screening of ovarian and/or breast cancer of sufficient sensitivity and specificity to avoid potential over-diagnosis, or; b) Stratification of patients into optimal personalised therapy regimes in ovarian/breast cancer. EpiFemCare ADVANCES Progress in personalised cancer medicine will only be possible with the development of bioassays involving the analysis of easy accessible biomaterials that contain stable target molecules reflective of disease. We will establish and clinically validate a series of blood tests based upon DNA methylation technology that will facilitate both early detection and prediction of therapeutic outcome in breast and ovarian cancer. CONSORTIUM Our pan-European academic-industrial consortium demonstrates diverse clinical, scientific & industrial expertise. We have access to the latest state of the art technologies and, integrally, the best available cohort and clinical trial sample sets required to ensure the success of the EpiFemCare program. GATC-Biotech and Genedata are Europes leading providers of DNA sequencing and bioinformatics for biomarker development and have developed serum DNA based prenatal tests. The clinical partners have access to unique cohort and clinical samples collected from >200,000 women well in advance of disease (UK Collaborative Trial of Ovarian Cancer Screening) or before and during treatment (SUCCESS Trial). IMPACT As a result of refined and improved patient stratification, EpiFemCare will: - Reduce the late stage presentation of ovarian & breast cancer by 50% - Reduce the requirement for 50% of breast cancer patients to have adjuvant therapies - Reduce female cancer related fatalities as well as treatment-related morbidity by 20%

Loading Genedata AG collaborators
Loading Genedata AG collaborators